Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Expression of nerve growth factor and heme oxygenase-1 predict poor survival of breast carcinoma patients

Authors: Sang Jae Noh, Jun Sang Bae, Urangoo Jamiyandorj, Ho Sung Park, Keun Sang Kwon, Sung Hoo Jung, Hyun Jo Youn, Ho Lee, Byung-Hyun Park, Myoung Ja Chung, Woo Sung Moon, Myoung Jae Kang, Kyu Yun Jang

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Nerve growth factor (NGF) is a neurotrophin and has been suggested to induce heme oxygenase-1 (HO1) expression. Although the role of HO1 in tumorigenesis remains controversial, recent evidence suggests NGF and HO1 as tumor-progressing factors. However, the correlative role of NGF and HO1 and their prognostic impact in breast carcinoma is unknown.

Methods

We investigated the expression and prognostic significance of the expression of NGF and HO1 in 145 cases of breast carcinoma.

Results

Immunohistochemical expression of NGF and HO1 was observed in 31% and 49% of breast carcinoma, respectively. The expression of NGF and HO1 significantly associated with each other, and both have a significant association with histologic grade, HER2 expression, and latent distant metastasis. The expression of NGF and HO1 predicted shorter overall survival of breast carcinoma by univariate and multivariate analysis. NGF expression was an independent prognostic indicator for relapse-free survival by multivariate analysis. The combined expression pattern of NGF and HO1 was also an independent prognostic indicator of overall survival and relapse-free survival. The patients with tumors expressing NGF had the shortest survival and the patients with tumor, which did not express NGF or HO1 showed the longest survival time.

Conclusions

This study has demonstrated that individual expression of NGF or HO1, and the combined NGF/HO1 expression pattern could be prognostic indicators for breast carcinoma patients.
Appendix
Available only for authorised users
Literature
1.
Kruttgen A, Schneider I, Weis J: The dark side of the NGF family: neurotrophins in neoplasias. Brain Pathol. 2006, 16: 304-310.CrossRefPubMed
2.
Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, Le Bourhis X, Boilly B, Peyrat JP, Hondermarck H: Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem. 2001, 276: 17864-17870.CrossRefPubMed
3.
Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, Le Bourhis X: Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer. 2010, 9: 157-CrossRefPubMedPubMedCentral
4.
Dang C, Zhang Y, Ma Q, Shimahara Y: Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer. J Gastroenterol Hepatol. 2006, 21: 850-858.CrossRefPubMed
5.
Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, Toillon RA, Oxombre B, Hondermarck H, Le Bourhis X: TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene. 2009, 28: 1960-1970.CrossRefPubMed
6.
Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R, Nurcombe V, Le Bourhis X, Hondermarck H: Nerve growth factor is a potential therapeutic target in breast cancer. Cancer research. 2008, 68: 346-351.CrossRefPubMed
7.
Dolle L, El Yazidi-Belkoura I, Adriaenssens E, Nurcombe V, Hondermarck H: Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene. 2003, 22: 5592-5601.CrossRefPubMed
8.
Naderi A, Hughes-Davies L: Nerve growth factor/nuclear factor-kappaB pathway as a therapeutic target in breast cancer. J Cancer Res Clin Oncol. 2009, 135: 211-216.CrossRefPubMed
9.
Tenhunen R, Marver HS, Schmid R: The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA. 1968, 61: 748-755.CrossRefPubMedPubMedCentral
10.
Otterbein LE, Soares MP, Yamashita K, Bach FH: Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 2003, 24: 449-455.CrossRefPubMed
11.
Schulz S, Wong RJ, Jang KY, Kalish F, Chisholm KM, Zhao H, Vreman HJ, Sylvester KG, Stevenson DK: Heme oxygenase-1 deficiency promotes the development of necrotizing enterocolitis-like intestinal injury in a newborn mouse model. Am J Physiol Gastrointest Liver Physiol. . in press
12.
13.
Banerjee P, Basu A, Wegiel B, Otterbein LE, Mizumura K, Gasser M, Waaga-Gasser AM, Choi AM, Pal S: Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. J Biol Chem. 2012, 287: 32113-32123.CrossRefPubMedPubMedCentral
14.
Kongpetch S, Kukongviriyapan V, Prawan A, Senggunprai L, Kukongviriyapan U, Buranrat B: Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. PLoS One. 2012, 7: e34994-CrossRefPubMedPubMedCentral
15.
Liu ZM, Chen GG, Ng EK, Leung WK, Sung JJ, Chung SC: Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene. 2004, 23: 503-513.CrossRefPubMed
16.
Maines MD, Abrahamsson PA: Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Urology. 1996, 47: 727-733.CrossRefPubMed
17.
Gandini NA, Fermento ME, Salomon DG, Blasco J, Patel V, Gutkind JS, Molinolo AA, Facchinetti MM, Curino AC: Nuclear localization of heme oxygenase-1 is associated with tumor progression of head and neck squamous cell carcinomas. Exp Mol Pathol. 2012, 93: 237-245.CrossRefPubMed
18.
Tsai JR, Wang HM, Liu PL, Chen YH, Yang MC, Chou SH, Cheng YJ, Yin WH, Hwang JJ, Chong IW: High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. Cell Oncol (Dordr). 2012, 35: 461-471.CrossRef
19.
Degese MS, Mendizabal JE, Gandini NA, Gutkind JS, Molinolo A, Hewitt SM, Curino AC, Coso OA, Facchinetti MM: Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. Lung Cancer. 2012, 77: 168-175.CrossRefPubMed
20.
Becker JC, Fukui H, Imai Y, Sekikawa A, Kimura T, Yamagishi H, Yoshitake N, Pohle T, Domschke W, Fujimori T: Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand J Gastroenterol. 2007, 42: 852-858.CrossRefPubMed
21.
Tsuji MH, Yanagawa T, Iwasa S, Tabuchi K, Onizawa K, Bannai S, Toyooka H, Yoshida H: Heme oxygenase-1 expression in oral squamous cell carcinoma as involved in lymph node metastasis. Cancer Lett. 1999, 138: 53-59.CrossRefPubMed
22.
Liu H, Nowak R, Chao W, Bloch KD: Nerve growth factor induces anti-apoptotic heme oxygenase-1 in rat pheochromocytoma PC12 cells. J Neurochem. 2003, 86: 1553-1563.CrossRefPubMed
23.
Salinas M, Diaz R, Abraham NG, Ruiz de Galarreta CM, Cuadrado A: Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. J Biol Chem. 2003, 278: 13898-13904.CrossRefPubMed
24.
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ: WHO Classification of Tumours of the Breast. 2012, Lyon, France: IARC
25.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual. 2009, New York: Springer, 7
26.
Allred D, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-PubMed
27.
Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Yu TK, Kim KM, Park HS, Lee J-H, Moon WS: Expression of SIRT1 and DBC1 Is Associated with Poor Prognosis of Soft Tissue Sarcomas. PloS one. 2013, 8: e74738-CrossRefPubMedPubMedCentral
28.
Moon WS, Jang KY, Chung MJ, Kang MJ, Lee DG, Lee H, Park HS: The expressions of nerve growth factor and its receptor p75NGFR in hepatocellular carcinoma: their relation with the clinicopathologic factors. Korean J Pathol. 2009, 43: 145-151.CrossRef
29.
Descamps S, Lebourhis X, Delehedde M, Boilly B, Hondermarck H: Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. J Biol Chem. 1998, 273: 16659-16662.CrossRefPubMed
30.
Demont Y, Corbet C, Page A, Ataman-Önal Y, Choquet-Kastylevsky G, Fliniaux I, Le Bourhis X, Toillon R-A, Bradshaw RA, Hondermarck H: Pro-nerve growth factor induces autocrine stimulation of breast cancer cell invasion through tropomyosin-related kinase A (TrkA) and sortilin protein. J Biol Chem. 2012, 287: 1923-1931.CrossRefPubMed
31.
Bassili M, Birman E, Schor NF, Saragovi HU: Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo. Cancer Chemother Pharmacol. 2010, 65: 1047-1056.CrossRefPubMed
32.
Tsang JY, Wong KH, Lai MW, Lacambra MD, Ko C-W, Chan SK, Lam CC, Alex M, Tan P-H, Gary MT: Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer. J Clin Pathol. 2013, 66: 291-296.CrossRefPubMed
33.
34.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006, 355: 2733-2743.CrossRefPubMed
35.
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005, 23: 4265-4274.CrossRefPubMed
36.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353: 1673-1684.CrossRefPubMed
37.
Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G, Melani C, Menard S: Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. J Biol Chem. 2000, 275: 5388-5394.CrossRefPubMed
38.
Bahmani P, Hassanshahi G, Halabian R, Roushandeh AM, Jahanian-Najafabadi A, Roudkenar MH: The expression of heme oxygenase-1 in human-derived cancer cell lines. Iran J Med Sci. 2011, 36: 260-265.PubMedPubMedCentral
39.
Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Kunzli B, Autschbach F, Meuer S, Buchler MW, Friess H: Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res. 2005, 11: 3790-3798.CrossRefPubMed
40.
Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, Matsuno S, Shibahara S, Abraham NG: Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis. 2003, 6: 15-24.CrossRefPubMed
41.
Miyake M, Fujimoto K, Anai S, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Matsumura Y, Tomioka A, Ikeda T, Tanaka N, Hirao Y: Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol Rep. 2011, 25: 653-660.CrossRefPubMed
42.
Gueron G, De Siervi A, Ferrando M, Salierno M, De Luca P, Elguero B, Meiss R, Navone N, Vazquez ES: Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol Cancer Res. 2009, 7: 1745-1755.CrossRefPubMed
43.
Hill M, Pereira V, Chauveau C, Zagani R, Remy S, Tesson L, Mazal D, Ubillos L, Brion R, Asghar K, Mashreghi MF, Kotsch K, Moffett J, Doebis C, Seifert M, Boczkowski J, Osinaga E, Anegon I: Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. FASEB J. 2005, 19: 1957-1968.CrossRefPubMed
44.
Lin CW, Shen SC, Hou WC, Yang LY, Chen YC: Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. Mol Cancer Ther. 2008, 7: 1195-1206.CrossRefPubMed
45.
Was H, Sokolowska M, Sierpniowska A, Dominik P, Skrzypek K, Lackowska B, Pratnicki A, Grochot-Przeczek A, Taha H, Kotlinowski J, Kozakowska M, Mazan A, Nowak W, Muchova L, Vitek L, Ratajska A, Dulak J, Jozkowicz A: Effects of heme oxygenase-1 on induction and development of chemically induced squamous cell carcinoma in mice. Free Radic Biol Med. 2011, 51: 1717-1726.CrossRefPubMedPubMedCentral
Metadata
Title
Expression of nerve growth factor and heme oxygenase-1 predict poor survival of breast carcinoma patients
Authors
Sang Jae Noh
Jun Sang Bae
Urangoo Jamiyandorj
Ho Sung Park
Keun Sang Kwon
Sung Hoo Jung
Hyun Jo Youn
Ho Lee
Byung-Hyun Park
Myoung Ja Chung
Woo Sung Moon
Myoung Jae Kang
Kyu Yun Jang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-516

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice

Research article

Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer

Study protocol

Effects of recreational soccer in men with prostate cancer undergoing androgen deprivation therapy: study protocol for the ‘FC Prostate’ randomized controlled trial

Research article

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

Research article

Heterogeneous echogenicity of the underlying thyroid parenchyma: how does this affect the analysis of a thyroid nodule?

Study protocol

Early-stage squamous cell carcinoma of the oropharynx: Radiotherapy vs. Trans-Oral Robotic Surgery (ORATOR) – study protocol for a randomized phase II trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits